Atara Biotherapeutics, Inc.
ATRA
$15.63
$1.6511.80%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -82.09% | 199.66% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -82.09% | 199.66% | |||
| Cost of Revenue | -98.60% | 11.28% | |||
| Gross Profit | -70.97% | 2,221.82% | |||
| SG&A Expenses | -40.72% | 6.05% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -74.05% | 10.18% | |||
| Operating Income | -90.29% | 498.39% | |||
| Income Before Tax | -93.71% | 399.01% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -93.72% | 399.46% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -93.72% | 399.46% | |||
| EBIT | -90.29% | 498.39% | |||
| EBITDA | -88.86% | 554.02% | |||
| EPS Basic | -94.46% | 397.94% | |||
| Normalized Basic EPS | -92.78% | 474.33% | |||
| EPS Diluted | -94.57% | 395.31% | |||
| Normalized Diluted EPS | -92.79% | 471.33% | |||
| Average Basic Shares Outstanding | 13.31% | 0.50% | |||
| Average Diluted Shares Outstanding | 13.45% | 1.32% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||